Date:
Saturday, September 22, 2012
Program Time:
8:00 AM – 4:00 PM (PT)
Location:
InterContinental Los Angeles Century City
2151 Avenue of the Stars
Los Angeles, CA 90067
Hotel Phone: (310) 284-6500
Hotel Accommodations:
Please see the Location tab for additional details.
This event is intended for clinicians in practice. There is no registration fee for this event. However, preregistration is required, as seating is limited.
Meeting Room:
Grand Salon Ballroom (Ground Floor)
Faculty:
Noncolorectal GI Cancers:
Charles D Blanke, MD
Vice-President, Systemic Therapy
British Columbia Cancer Agency
Head, Division of Medical Oncology
University of British Columbia
Vancouver, British Columbia, Canada
Breast Cancer:
Harold J Burstein, MD, PhD
Associate Professor of Medicine
Harvard Medical School
Breast Oncology Center
Dana-Farber Cancer Institute
Boston, Massachusetts
Prostate Cancer and
Renal Cell Carcinoma:
Toni K Choueiri, MD
Director, Kidney Cancer Center
Lank Center for Genitourinary Oncology
Dana-Farber Cancer Institute/Brigham and Women’s Hospital
Harvard Medical School
Boston, Massachusetts
Multiple Myeloma:
Rafael Fonseca, MD
Getz Family Professor of Cancer
Chair, Department of Internal Medicine
Associate Director, Center for
Individualized Medicine
Mayo Clinic Arizona
Scottsdale, Arizona
Chronic Myeloid Leukemia:
Hagop M Kantarjian, MD
Chairman and Professor
Leukemia Department
The University of Texas
MD Anderson Cancer Center
Houston, Texas
Colorectal Cancer:
Alan P Venook, MD
Professor of Clinical Medicine
University of California, San Francisco
San Francisco, California
Non-Small Cell Lung Cancer:
Heather Wakelee, MD
Assistant Professor of Medicine
Division of Oncology
Stanford University School of Medicine
Stanford Cancer Institute
Stanford, California
Dermatologic Oncology:
Jeffrey Weber, MD, PhD
Senior Member
H Lee Moffitt Cancer Center
Director, Donald A Adam Comprehensive
Melanoma Research Center
Tampa, Florida
Moderator:
Neil Love, MD
Research To Practice
Miami, Florida
8:00 AM Dr Love — Introduction
Attendees will be provided with a networked iPad to use during the meeting to participate in a premeeting survey, view the details of the faculty answer matrices and related data slides and ask questions to stimulate additional discussion.
8:05 AM Dr Burstein — MODULE 1: Breast Cancer
Key Publications and Presentations Related to the Following Topics Will Be Reviewed:
- Current and future management of HER2-positive early and advanced breast cancer
- Triple-negative and/or BRCA mutation-positive breast cancer
- Novel treatment approaches in the management of ER-positive metastatic breast cancer
- Sequence of chemotherapy in the metastatic setting
- Ongoing clinical trials of new agents and regimens
Q&A Session
8:55 AM Dr Weber — MODULE 2: Dermatologic Oncology
Key Publications and Presentations Related to the Following Topics Will Be Reviewed:
- Current role and timing of BRAF mutation testing
- Sequencing available therapeutic agents for patients with or without BRAF V600E mutations
- Incidence and management of secondary cutaneous lesions with vemurafenib
- Common immune-related adverse events associated with ipilimumab
- Other novel targeted agents under development for metastatic melanoma
- Overall incidence of and factors affecting progression to advanced-stage basal cell carcinoma (BCC)
- Data supporting current management strategies in advanced BCC
- Current treatment of locally advanced and metastatic squamous cell carcinoma
Q&A Session
9:45 AM Dr Fonseca — MODULE 3: Multiple Myeloma
Key Publications and Presentations Related to the Following Topics Will Be Reviewed:
- Clinical use of metaphase and FISH cytogenetics
- Selection of doublet and triplet regimens in transplant-eligible multiple myeloma (MM)
- Therapeutic decision-making for patients ineligible for transplant
- Bortezomib schedule and method of administration
- Individualized use of maintenance approaches and incidence of second primary cancers
- Second-generation IMiDs and proteasome inhibitors
- Ongoing clinical trials of new agents and regimens
Q&A Session
Morning Break
10:50 AM Dr Wakelee — MODULE 4: Non-Small Cell Lung Cancer
Key Publications and Presentations Related to the Following Topics Will Be Reviewed:
- Adjuvant treatment of non-small cell lung cancer (NSCLC)
- Histology and choice of chemotherapy and/or biologic treatment
- Long-term care of patients with EGFR mutations or the EML4-ALK fusion oncogene
- Optimal first-line therapy for patients with EGFR wild-type disease
- Maintenance approaches to metastatic NSCLC
- Active experimental agents in NSCLC
Q&A Session
11:40 AM Dr Blanke — MODULE 5: Noncolorectal GI Cancers
Key Publications and Presentations Related to the Following Topics Will Be Reviewed:
- Clinical and investigational approaches to the best-practice management of HER2-negative and HER2-positive gastric cancer
- Challenges and uncertainties in the diagnosis and management of GI neuroendocrine tumors
- Individualized local and systemic treatment approaches to hepatocellular carcinoma (HCC)
- Therapeutic options and future research directions in HCC
- Optimal systemic management of resectable and advanced gastrointestinal stromal tumors (GIST)
- Novel treatment strategies in the management of advanced pancreatic adenocarcinoma
Q&A Session
Lunch
1:15 PM Dr Venook — MODULE 6: Colorectal Cancer
Key Publications and Presentations Related to the Following Topics Will Be Reviewed:
- Optimal (neo)adjuvant therapy for colorectal cancer (CRC)
- Emerging biomarkers and gene signatures to refine decision-making for patients
- Sequencing agents and regimens in metastatic CRC
- Benefits and risks of anti-VEGF and anti-EGFR treatment approaches
- Management of liver-only metastatic and synchronous primary and metastatic CRC
- New agents and strategies in CRC: aflibercept, regorafenib, et cetera
Q&A Session
2:05 PM Dr Kantarjian — MODULE 7: Chronic Myeloid Leukemia
Key Publications and Presentations Related to the Following Topics Will Be Reviewed:
- Sequencing available TKIs (tyrosine kinase inhibitors) (imatinib, nilotinib, dasatinib) to optimize long-term outcomes
- Management of toxicities associated with chronic use of first- and second-generation TKI therapy
- Clinical relevance of cytogenetic and/or molecular response at various stages of follow-up
- Discerning therapeutic resistance versus noncompliance in chronic myeloid leukemia (CML)
- Indications for and practical use of ABL kinase domain mutation testing
- Investigational agents in CML (eg, bosutinib, ponatinib, farnesyl transferase inhibitors)
Q&A Session
Afternoon Break
3:10 PM Dr Choueiri — MODULE 8: Prostate Cancer and Renal Cell Carcinoma
Key Publications and Presentations Related to the Following Topics Will Be Reviewed:
- Rational selection and sequencing of available systemic agents in the management of asymptomatic and symptomatic castration-resistant prostate cancer
- Role of palliative radiation and radiopharmaceuticals in the management of symptomatic skeletal metastases
- Evidence-based utility of bone-directed treatment of prostate cancer
- Rational sequencing of multitargeted TKIs, VEGF monoclonal antibodies, mTOR inhibitors, VEGFR-specific TKIs and cytokines in the management of renal cell carcinoma (RCC)
- Management of treatment-induced toxicities
- Novel agents and strategies under investigation in advanced prostate cancer and RCC
Q&A Session
4:00 PM — Close
Target Audience:
This educational activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows and other oncology healthcare professionals.
Learning Objectives and Goals:
- Effectively apply the results of practice-changing
clinical research to the care
of patients with breast, lung, gastrointestinal,
genitourinary, skin and select
hematologic cancers.
- Compare and contrast the clinical
relevance of recent pivotal cancer
research results published in peer-reviewed
journals and/or presented at
major oncology conferences.
- Recall ongoing trials in breast, lung,
gastrointestinal, genitourinary, skin
and select hematologic cancers, and
refer appropriate patients for study
participation.
- Utilize an understanding of tumor
biomarkers and single and multigene
signatures to individualize the care of
patients with cancer.
- Educate patients with diverse hematologic
cancers and solid tumors about the
benefits and risks of new therapeutic
agents and strategies.
- Employ case-based learning to refine or
validate existing cancer-specific treatment
algorithms.
CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.
Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure Policy:
As a provider accredited by the Accreditation Council for Continuing Medical Education, it is the policy of Research To Practice to require the disclosure of any significant financial interest or any other relationship the sponsor or faculty members have with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. Financial disclosures and disclosures of discussions of unlabeled/unapproved uses of drugs or devices will be provided in meeting course materials.
This activity is supported by educational grants from Astellas, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Lilly USA LLC, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Regeneron Pharmaceuticals and Sanofi.
InterContinental Los Angeles Century City
2151 Avenue of the Stars
Los Angeles, CA 90067
Hotel Phone: (310) 284-6500
Meeting Room: Grand Salon Ballroom (Ground Floor)
Room Reservations
Please contact the InterContinental Los Angeles Century City hotel for reservations at (866) 385-1943 for current best room rates and availability. Make sure you use reference code Year in Review 2012. For further assistance, please contact our Meeting Services department at (800) 233-6153.
Seats are still available for the program. Online preregistration is closed but onsite registration will be open starting at 7:15 AM (Pacific Time) on Saturday, September 22nd. If you are interested in attending, please visit our registration desk located in the Grand Salon Foyer on the ground floor of the InterContinental Los Angeles Century City hotel (2151 Avenue of the Stars, Los Angeles, CA).
We will accept new registrations on a first come, first served basis. If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com or call (800) 233-6153.
|
